387 related articles for article (PubMed ID: 27023465)
1. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Gao C; Tong J; Yu K; Sun Z; An R; Du Z
Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cefoperazone/sulbactam in critically Ill thrombotic thrombocytopenic purpura patients undergoing therapeutic plasma exchange.
Li H; Gao C; Lin L; Zhang G; Fan S; Hai X
J Clin Pharm Ther; 2022 Aug; 47(8):1232-1239. PubMed ID: 35347732
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
6. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
[TBL] [Abstract][Full Text] [Related]
10. [In vitro resistance development in Acinetobacter baumannii to sulbactam and cefoperazone].
Wieczorek P; Sacha P; Ojdana D; Milewski R; Jurczak A; Kaczyńska K; Tryniszewska E
Med Dosw Mikrobiol; 2012; 64(1):55-62. PubMed ID: 22808730
[TBL] [Abstract][Full Text] [Related]
11. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
Sivagurunathan N; Krishnan S; Rao JV; Nagappa AN; Subrahmanyam VM; Vanathi BM
J Med Microbiol; 2008 Dec; 57(Pt 12):1514-1517. PubMed ID: 19018022
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid.
Janssen PK; Foudraine NA; Burgers DM; Neef K; le Noble JL
Ther Drug Monit; 2016 Dec; 38(6):699-705. PubMed ID: 27494946
[TBL] [Abstract][Full Text] [Related]
14. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger LH; Piscitelli SC; Occhipinti DJ; Resnick DJ; Rodvold KA
Ann Pharmacother; 1994 Jun; 28(6):703-7. PubMed ID: 7919553
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Muder RR; Agarwala S; Mirani A; Gayowski T; Venkataramanan R
J Clin Pharmacol; 2002 Jun; 42(6):644-50. PubMed ID: 12043952
[TBL] [Abstract][Full Text] [Related]
17. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Schwartz JI; Jauregui LE; Bachmann KA; Martin ME; Reitberg DP
Antimicrob Agents Chemother; 1988 May; 32(5):730-5. PubMed ID: 3395103
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
Pei G; Mao Y; Sun Y
Microb Drug Resist; 2012 Dec; 18(6):574-7. PubMed ID: 22928863
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
